{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-010435","form_type":"8-K","ticker":"QSI","cik":"0001816431","company_name":"Quantum-Si Inc","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.653109+00:00","generated_at":"2026-06-05T07:14:00.113413+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Quantum-Si Q4 rev $400k, net loss $22M; full commercial launch expected by end Q1 2024","bullets":["Revenue $400k in Q4 2023, $1.1M for FY2023; gross margin 45%.","Net loss narrowed to $22.0M in Q4 ($96.0M FY) from $33.1M ($132.4M FY) prior year.","Expects full commercial launch of Platinum instrument by end of Q1 2024; version 2 sequencing kit already shipping.","Version 3 sequencing kit planned for release by end of Q3 2024.","Third international distribution partner TOMY Digital Biology (Japan) added."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-010435","json":"https://secwatch.observer/filing/0001140361-24-010435.json","markdown":"https://secwatch.observer/filing/0001140361-24-010435.md","text":"https://secwatch.observer/filing/0001140361-24-010435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816431/000114036124010435/0001140361-24-010435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816431/000114036124010435/ef20022499_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:14:00.113413+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7f060525e161e40fb25148161c94d75e0664cb17","claim":"Quantum-Si Inc reported the full year ended December 31, 2023 results: revenue $1.1 million, net income $96.0 million. Guidance initiated.","evidence_excerpt":"For the full year ended December 31, 2023, the Company recorded revenue of $1.1 million, gross profit of $488,000, and gross margin of 45%. The periodic gross margin rate is expected to be variable in the near term as the Company works through the initial stages of commercialization as well as the timing and mix of product sales between instruments and consumable kits. Total operating expenses were $28.1 million in the fourth quarter of 2023, compared to $38.8 million for the same period in the prior year, and $111.7 million for the full year ended December 31, 2023, compared to $123.8 million for the same period in the prior year. Adjusted total operating expenses were $26.3 million in the fourth quarter of 2023, compared to $25.3 million for the same period in the prior year, and adjusted total operating expenses for the full year ended December 31, 2023, were $98.9 million compared to $103.2 million for the same period in the prior year. Overall adjusted operating expenses for 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816431/000114036124010435/0001140361-24-010435-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"$1.1 million"},{"label":"Net income","value":"$96.0 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"efb05a633f51976d506ef71b1c32a2debbeb67e0","claim":"Quantum-Si Inc reported the fourth quarter ended December 31, 2023 results: revenue $400,000, net income $22.0 million. Guidance initiated.","evidence_excerpt":"During the fourth quarter of 2023, the Company continued its controlled commercial launch of its Platinum instrument, recording revenue of $400,000. Gross profit was $178,000 and gross margin was 45%. For the full year ended December 31, 2023, the Company recorded revenue of $1.1 million, gross profit of $488,000, and gross margin of 45%. The periodic gross margin rate is expected to be variable in the near term as the Company works through the initial stages of commercialization as well as the timing and mix of product sales between instruments and consumable kits. Total operating expenses were $28.1 million in the fourth quarter of 2023, compared to $38.8 million for the same period in the prior year, and $111.7 million for the full year ended December 31, 2023, compared to $123.8 million for the same period in the prior year. Adjusted total operating expenses were $26.3 million in the fourth quarter of 2023, compared to $25.3 million for the same period in the prior year, and adjust","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816431/000114036124010435/0001140361-24-010435-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$400,000"},{"label":"Net income","value":"$22.0 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}